Clinical Trials
226
Trial Phases
4 Phases
Drug Approvals
78
Drug Approvals
Enzalutamide Soft Capsules
- Product Name
- 恩扎卢胺软胶囊
- Approval Number
- 国药准字HJ20240126
- Approval Date
- Oct 29, 2024
Erlotinib Hydrochloride Tablets
- Product Name
- 盐酸厄洛替尼片
- Approval Number
- 国药准字HJ20240114
- Approval Date
- Oct 22, 2024
Erlotinib Hydrochloride Tablets
- Product Name
- 盐酸厄洛替尼片
- Approval Number
- 国药准字HJ20240115
- Approval Date
- Oct 22, 2024
Lurasidone Hydrochloride Tablets
- Product Name
- 盐酸鲁拉西酮片
- Approval Number
- 国药准字HJ20230104
- Approval Date
- Sep 5, 2023
Clopidogrel Bisulfate Tablets
- Product Name
- 硫酸氢氯吡格雷片
- Approval Number
- 国药准字HJ20180074
- Approval Date
- Jul 7, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (222 trials with phase data)• Click on a phase to view related trials
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Test ProductDrug: Reference productDrug: Reference Medicinal Product
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 330
- Registration Number
- NCT06126042
- Locations
- 🇺🇸
ICON, plc., Lenexa, Kansas, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸ICON, Salt Lake City, Utah, United States
Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection
- Conditions
- COVID-19 Prevention
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 1600
- Registration Number
- NCT04640233
- Locations
- 🇮🇳
S N Medical College, Agra, India
🇮🇳MGM Medical College and Hospital, Aurangabad, India
🇮🇳KLE Prabhakar Kore Hospital, Belgaum, India
Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 353
- Registration Number
- NCT04529499
- Locations
- 🇰🇼
Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait
🇰🇼Mishref Field Hospital (Mishref), Kuwait City, Kuwait
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 140
- Registration Number
- NCT04268771
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸California Allergy and Asthma Medical Group - CRN - PPDS 41230 11th Street West, Suite A, Palmdale, California, United States
🇺🇸Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 317
- Registration Number
- NCT03976102
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸American Oncology Partners of Maryland, Bethesda, Maryland, United States
🇺🇸University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 45
- Next